TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3306374
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (30 mg/kg)
Study: 26872958
Drug: Acceptance-Based Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-Based Behavioral Treatment (ABBT)
Study: 26872958
Drug: Traditional Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Cognitive-Behavioral Treatment (tCBT)
Study: 24305788
Drug: Pre-operative autologous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative autologous blood donation (PABD) - 1 dose 72 hours prior to TKA
Study: 23774876
Drug: Ritonavir-boosted elvitegravir
Normalized name: Elvitegravir
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ritonavir-boosted elvitegravir (EVG/r; 50/100 mg QD) administered alone or with antacid simultaneously
Study: 23774876
Drug: Cobicistat-boosted elvitegravir
Normalized name: cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobicistat-boosted elvitegravir (EVG/co; 150/150 mg QD) administered simultaneously or staggered (+12 hours) with famotidine or omeprazole
Study: 23774876
Drug: Staggered antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staggered antacid administration by ≥2 hours
Study: 15752122
Drug: PUVA-gel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA-gel therapy (aqueous 8-methoxypsoralen (8-MOP)-containing gel plus broadband UVA irradiation)
Study: 15752122
Drug: PUVA-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA-bath therapy (8-MOP bath of the hands and/or feet plus broadband UVA)
Study: 11812684
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia (TEA) with ropivacaine 1% (4‐mL bolus, 3‐5 mL/h infusion), fentanyl (100‐microg bolus, 15‐25 microg/h infusion), and propofol infusion (6 mg x kg(‐1) x h(‐1))
Study: 11812684
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia with fentanyl (15 microg/kg) and propofol (5 mg x kg(‐1) x h(‐1)), followed by IV morphine patient‐controlled analgesia
Study: 1836919
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV
Study: 1836919
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Group III)
Study: 1836919
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Groups I and II)
Study: 7222859
Drug: Intravenous tinofedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tinofedrine (0.12 to 0.17 mg/kg body‐weight)
Study: 30098134
Drug: Insulin-stimulated brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated brain glucose uptake (BGU) in obese participants
Study: 30098134
Drug: Insulin-stimulated brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated brain glucose uptake (BGU) in obese participants post-bariatric surgery
Study: 30098134
Drug: High insulin-stimulated
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin-stimulated BGU at baseline
Study: 30098134
Drug: Insulin-stimulated brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated brain glucose uptake (BGU) in all participants
Study: 23751236
Drug: 1000mcg chromium/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mcg chromium/day (high dose)
Study: 23751236
Drug: 600mcg chromium/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mcg chromium/day (moderate dose)
Study: 19090875
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (3 doses)
Study: 9062374
Drug: Antidepressants (sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (sertraline and imipramine)
Study: 3085552
Drug: Fentanyl 3
Normalized name: FENTANYL 37.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 3 micrograms/kg plus continuous intravenous nitroglycerin infusion 0.9 microgram X kg‐1 X min‐1 (group 3, n = 20)
Study: 30182786
Drug: JNJ-42847922 (5-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42847922 (5-60 mg orally once daily for 10 days)
Study: 30182786
Drug: JNJ-42847922 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42847922 (doses >5 mg)
Study: 30182786
Drug: JNJ-42847922 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42847922 (doses >10 mg)
Study: 27154159
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg intravenous methylprednisolone
Study: 22864179
Drug: Omeprazole 10mg
Normalized name: OMEPRAZOLE 10MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 10mg daily
Study: 22864179
Drug: Famotidine 20mg
Normalized name: FAMOTIDINE 20MG TAB
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 20mg daily
Study: 21260940
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of oxibutinin
Study: 21260940
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (intravesical electroneurostimulation and magnetophoresis)
Study: 18832294
Drug: Ambrisentan 10
Normalized name: ambrisentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 10 mg alone
Study: 18832294
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg 3 times daily after 7 days of ambrisentan 10 mg once daily
Study: 15963399
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (500 to 1,000 mg) plus hypertonic saline solution (HSS) twice a day for four to six days
Study: 15963399
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (500 to 1,000 mg) alone, twice a day for four to six days
Study: 31969977
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 International Units once daily for 4 weeks)
Study: 25701159
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition with glutamine supplementation (SPN + Gln)
Study: 23798635
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (SPN)
Study: 19539361
Drug: Rivaroxaban (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (5-20 mg, once daily or twice daily)
Study: 17292895
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU of recombinant follicle-stimulating hormone (FSH) as the control group (group A)
Study: 17292895
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU of recombinant FSH plus daily supplementation with 75 IU of recombinant luteinizing hormone (group B)
Study: 17292895
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU of recombinant FSH plus daily supplementation with 75 IU of recombinant hCG (group C)
Study: 11575982
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg, orally, 4 times daily for 2 days
Study: 11575982
Drug: Placebo, orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, 4 times daily for 2 days
Study: 10230643
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy with metformin
Study: 10230643
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy without metformin
Study: 826960
Drug: Adrenaline injections
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injections
Study: 26534874
Drug: 400μg buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400μg buccal misoprostol
Study: 26534874
Drug: 800μg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800μg placebo buccal
Study: 20508907
Drug: Idraparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idraparinux (2.5 mg, once-weekly subcutaneous injection)
Study: 20508907
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (heparin followed by vitamin K antagonists)
Study: 8142791
Drug: Self-directed treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed treatment manual
Study: 2131504
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids supplementation added to a protein restricted diet (0.6 g/kg/day)
Study: 134723
Drug: ipratropiumbromide (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipratropiumbromide (0.02 mg per puff, 3 x 2 puffs)
Study: 25913498
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 35 mg b.i.d. (which could be increased to t.i.d. as needed)
Study: 19207134
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) 10 mmol
Study: 15109586
Drug: Pharmacological or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological or surgical treatment
Study: 2587002
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 cycles)
Study: 2587002
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and surgery or radiotherapy
Study: 29488475
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs and an anxiolytic (adaptol)
Study: 23158073
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs only
Study: 19308789
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg caffeine . kg(‐1) body mass (BM)
Study: 19308789
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg caffeine . kg(‐1) BM
Study: 20816042
Drug: Armodafinil 100
Normalized name: armodafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 100 mg
Study: 16393442
Drug: Armodafinil 300
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Armodafinil 300 mg
Study: 9396910
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of dexamethasone in saline solution (study group, n = 50)
Study: 9396910
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution only (control group, n = 48)
Study: 29522941
Drug: Bupropion-SSRI combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion-SSRI combination
Study: 27622558
Drug: Scheduled intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intermittent screening with malaria rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine (ISTp-DP)
Study: 27622558
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive therapy with sulfadoxine-pyrimethamine (IPTp-SP)
Study: 24755129
Drug: Ticagrelor 600
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 600 mg (SAD study)
Study: 24755129
Drug: Ticagrelor 100
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 100 mg and 300 mg (MAD study)
Study: 24755129
Drug: Ticagrelor >=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor >= 100 mg (SAD study)
Study: 20502014
Drug: Rivastigmine 17.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 17.4 mg/24 h patch
Study: 20502014
Drug: Rivastigmine 9.5
Normalized name: RIVASTIGMINE 9.5MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 9.5 mg/24 h patch
Study: 20502014
Drug: Rivastigmine patches
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patches and capsules
Study: 16042935
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (ALA) and intense pulsed light (IPL)
Study: 12443968
Drug: 1.0% C31G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% C31G co-polymer gel
Study: 12443968
Drug: 1.2% HEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% HEC gel
Study: 375850
Drug: Naproxen at
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen at 10 mg per kg body weight
Study: 375850
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at 80 mg per kg body weight
Study: 28107821
Drug: Letrozole 20
Normalized name: ribociclib succinate/letrozole 200 mg/day (200 mg x 1)-2.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 20 mg administered when the dominant follicle reached 12 mm
Study: 28107821
Drug: Letrozole 20
Normalized name: ribociclib succinate/letrozole 200 mg/day (200 mg x 1)-2.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 20 mg administered when the dominant follicle reached 18 mm
Study: 28107821
Drug: Letrozole 20
Normalized name: ribociclib succinate/letrozole 200 mg/day (200 mg x 1)-2.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 20 mg administered on the first day following ovulation (post‐ovulation)
Study: 28107821
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment withheld)
Study: 27186989
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhalers (MDIs) with spacers
Study: 15979021
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 150 mg
Study: 8961722
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dextroamphetamine (10 mg doses at midnight, 4 a.m., and 8 a.m.)
Study: 1301641
Drug: Meperidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine administered via femoral block
Study: 1301641
Drug: Meperidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine administered intravenously
Study: 1301641
Drug: Meperidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine administered via interscalene block
Study: 3886301
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg) with chlorthalidone (12.5 mg)
Study: 3886301
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg) alone
Study: 3886301
Drug: Chlorthalidone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5 mg) alone
Study: 16416000
Drug: Hugan tablets
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hugan tablets
Study: 26382733
Drug: Epratuzumab 100
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab 100 mg Q2W
Study: 26382733
Drug: Epratuzumab 400
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab 400 mg Q2W
Study: 26382733
Drug: Epratuzumab 600
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab 600 mg QW
Study: 26382733
Drug: Epratuzumab 1200
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab 1200 mg Q2W
Study: 26382733
Drug: Epratuzumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab (all doses)
Study: 15681764
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (1 mg/day)
Study: 15681764
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (10 mg/day)
Study: 11120935
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg orally, 3 times per week for 6 months
Study: 9613081
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of long-acting propranolol hydrochloride-betacap (Natko, India)
Study: 7626966
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors (treatment duration: 10 to 12 weeks)
Study: 1720479
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 or 5 mg b.i.d.)
Study: 1720479
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 or 25 mg b.i.d.)
Study: 6184938
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with dextran
Study: 31138247
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin infusion (10 ml/kg) administered slowly (180 min)
Study: 31138247
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin infusion (10 ml/kg) administered rapidly (30 min)
Study: 22746358
Drug: Physiotherapist-guided pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist-guided pelvic floor muscle training (PFMT) once weekly for 12 months (Group A, n=42)
Study: 11422148
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast (10 mg tablet for adults, 5 mg chewable tablet for children)
Study: 11422148
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (beclomethasone 200 microg twice daily for adults, 100 microg or equivalent three times daily for children)
Study: 9727891
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg troglitazone
Study: 9727891
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg troglitazone
Study: 31469243
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8mg/kg intravenous infusions
Study: 31469243
Drug: Etanercept 50mg
Normalized name: ETANERCEPT 50MG/ML INJ SYRINGE
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50mg subcutaneous injections
Study: 28634121
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (300 mg, twice daily)
Study: 24301236
Drug: Abobotulinum toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abobotulinum toxin A (ABO) at doses ranging from 120 to 250 U
Study: 24301236
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of ABO in the perioral area
Study: 19584187
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (0.012 mg/kg every second day, approximately 2.5 IU)
Study: 17582635
Drug: Slow-releasing drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-releasing drug-eluting stents (sirolimus and paclitaxel)
Study: 17582635
Drug: Rapid-releasing drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-releasing drug-eluting stents (sirolimus and paclitaxel)
Study: 16260342
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (0.4 mg)
Study: 11394732
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupropion SR and nicotine patch
Study: 31509849
Drug: Needle penetration
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle penetration without injection (placebo)
Study: 30912296
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (GT) treatment for 4 months
Study: 30912296
Drug: Hot water
Normalized name: hot water bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot water (HW) ingestion for 4 months (after GT treatment in Grp1)
Study: 30912296
Drug: Hot water
Normalized name: hot water bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot water (HW) ingestion for 4 months (before GT treatment in Grp2)
Study: 30912296
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (GT) treatment for 4 months (after HW ingestion in Grp2)
Study: 28712591
Drug: SPIOMET (spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPIOMET (spironolactone 50 mg/d, pioglitazone 7.5 mg/d, metformin 850 mg/d)
Study: 25130321
Drug: Medications associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications associated with weight gain
Study: 23230066
Drug: 0 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg/day iron supplementation (placebo)
Study: 23230066
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day iron supplementation
Study: 23230066
Drug: 2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day iron supplementation
Study: 18837739
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (750 mg daily)